- Home
- MTVA
MTVA
METAVIA INC
as 12-18-2024 4:00pm EST
Stocks
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 18.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 256.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.55 - $6.75 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest METAVIA INC News
MTVA Breaking Stock News: Dive into MTVA Ticker-Specific Updates for Smart Investing
PR Newswire
9 hours ago
MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
ACCESSWIRE
15 days ago
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
GlobeNewswire
15 days ago
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
Zacks Small Cap Research
15 days ago
MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…
PR Newswire
16 days ago
MetaVia to Present at the Emerging Growth Conference in December
Compare MTVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MTVA METAVIA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.